Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/FJC.0000000000000223 http://scihub22266oqcxt.onion/10.1097/FJC.0000000000000223 C4461390!4461390!25636071     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Cardiovasc+Pharmacol 2015 ; 65 (6): 555-61 Nephropedia Template TP {{tp|p=25636071|t=2015. Erythropoietin Reduces Post-PCI Arrhythmias in Patients With ST-elevation Myocardial Infarction |pdf=|usr=}}{{25636071}} gab.com Text Erythropoietin Reduces Post-PCI Arrhythmias in Patients With ST-elevation Myocardial Infarction JO: J Cardiovasc Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=25636071 #FOAvip Background:: Arrhythmia is the foremost cause of sudden death after myocardial infarction (MI). Animal models have recently shown that erythropoietin (EPO) can reduce the incidence of arrhythmia after MI. Methods:: We investigated the effects of administrating 33,000 IU EPO on the occurrence of post-MI arrhythmia in 40 patients with ST-elevation MI who were randomly assigned in either EPO or placebo groups. Arrhythmias were blindly documented using full 12-lead configuration during 24 hours after percutaneous coronary intervention (PCI) by a cardiologist. Afterward, CK-MB, hematologic, and hemodynamic data were examined within 2 weeks after MI. Results:: A comparison made between the 2 groups showed significant differences in the incidence of arrhythmias (20% in EPO group and 35% in placebo group, P = 0.043). However, no significant differences in type of arrhythmias were observed between the groups. There was no significant difference between levels of CK-MB in the 2 groups during 24 hours (P = 0.186). Hematologic and hemodynamic data showed no significant changes 2 weeks after PCI. Conclusion:: High-dose administration of EPO in patients with ST-elevation MI who have been treated by primary PCI and standard antiplatelet therapy reduces the occurrence of arrhythmias. For clinical interpretation of the results, further well-designed trials are required. Twit Text FOAVip Erythropoietin Reduces Post-PCI Arrhythmias in Patients With ST-elevation Myocardial Infarction ????J Cardiovasc Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=25636071 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25636071 #FOAvip English Wikipedia <ref>{{Cite pmid|25636071}}</ref> Erythropoietin Reduces Post-PCI Arrhythmias in Patients With ST-elevation Myocardial Infarction #MMPMID25636071 Gholamzadeh A; Amini S; Mohammadpour AH; Vahabzadeh M; Fazelifar AF; Fazlinezhad A; Dehghani M; Moohebati M; Dastani M; Malaekeh-Nikouie B; Falsoleiman H J Cardiovasc Pharmacol 2015[Jun]; 65 (6): 555-61 PMID25636071show ga Background:: Arrhythmia is the foremost cause of sudden death after myocardial infarction (MI). Animal models have recently shown that erythropoietin (EPO) can reduce the incidence of arrhythmia after MI. Methods:: We investigated the effects of administrating 33,000 IU EPO on the occurrence of post-MI arrhythmia in 40 patients with ST-elevation MI who were randomly assigned in either EPO or placebo groups. Arrhythmias were blindly documented using full 12-lead configuration during 24 hours after percutaneous coronary intervention (PCI) by a cardiologist. Afterward, CK-MB, hematologic, and hemodynamic data were examined within 2 weeks after MI. Results:: A comparison made between the 2 groups showed significant differences in the incidence of arrhythmias (20% in EPO group and 35% in placebo group, P = 0.043). However, no significant differences in type of arrhythmias were observed between the groups. There was no significant difference between levels of CK-MB in the 2 groups during 24 hours (P = 0.186). Hematologic and hemodynamic data showed no significant changes 2 weeks after PCI. Conclusion:: High-dose administration of EPO in patients with ST-elevation MI who have been treated by primary PCI and standard antiplatelet therapy reduces the occurrence of arrhythmias. For clinical interpretation of the results, further well-designed trials are required. äErythropoietin Reduces Post-PCI Arrhythmias in Patients With ST-elevat(epmc).pdf DeepDyve Pubget Overpricing